ICTM logo
DART presentations at CROI

23 February 2010

Two oral presentations at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted further results from the DART trial.

The first explored the risk of getting different HIV-related events and dying according to the CD4 cell count (a measure of the body's ability to fight HIV).

The second investigated how much CD4 cell counts increased over 5 years on anti-HIV drugs.

  1. Risk of WHO 4 events and death by current CD4 on ART in the DART trial: the impact of CD4-dependent reporting bias. Presented on Wednesday 17 February.  17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco USA
  2. Immune restoration over 5 years on ART among patients initiating treatment with advanced immune deficiency in the DART trial in Uganda and Zimbabwe. Presented on Thursday 18 February. 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco USA